Acrux Limited (ARUXF)
USD 0.04
(13.64%)
USD 0.04
(13.64%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -8.57 Million AUD | -179.41% |
| 2023 | -3.06 Million AUD | 76.33% |
| 2022 | -12.96 Million AUD | 20.21% |
| 2021 | -16.25 Million AUD | -34.56% |
| 2020 | -12.07 Million AUD | 7.03% |
| 2019 | -12.99 Million AUD | -143.53% |
| 2018 | -5.33 Million AUD | -125.11% |
| 2017 | 21.24 Million AUD | 10.06% |
| 2016 | 19.3 Million AUD | 14.14% |
| 2015 | 16.91 Million AUD | -63.57% |
| 2014 | 46.43 Million AUD | 390.67% |
| 2013 | 9.46 Million AUD | 189.48% |
| 2012 | 3.26 Million AUD | -96.08% |
| 2011 | 83.31 Million AUD | 68.61% |
| 2010 | 49.41 Million AUD | 567.3% |
| 2009 | -10.57 Million AUD | -39.94% |
| 2008 | -7.55 Million AUD | 23.25% |
| 2007 | -9.84 Million AUD | 19.91% |
| 2006 | -12.29 Million AUD | -103.4% |
| 2005 | -6.04 Million AUD | -42.8% |
| 2004 | -4.23 Million AUD | 28.86% |
| 2003 | -5.94 Million AUD | -55.07% |
| 2002 | -3.83 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -8.57 Million AUD | -179.41% |
| 2024 Q2 | -4.22 Million AUD | -378.04% |
| 2024 Q4 | -4.34 Million AUD | -2.77% |
| 2023 Q4 | 1.52 Million AUD | 130.97% |
| 2023 Q2 | -4.91 Million AUD | 21.55% |
| 2023 FY | -3.06 Million AUD | 76.33% |
| 2022 FY | -12.96 Million AUD | 20.21% |
| 2022 Q4 | -6.26 Million AUD | 6.65% |
| 2022 Q2 | -6.7 Million AUD | 19.33% |
| 2021 Q4 | -8.31 Million AUD | -4.72% |
| 2021 FY | -16.25 Million AUD | -34.56% |
| 2021 Q2 | -7.93 Million AUD | -31.32% |
| 2020 FY | -12.07 Million AUD | 7.03% |
| 2020 Q4 | -6.04 Million AUD | -0.22% |
| 2020 Q2 | -6.03 Million AUD | 15.03% |
| 2019 FY | -12.99 Million AUD | -143.53% |
| 2019 Q2 | -3.83 Million AUD | 15.63% |
| 2019 Q4 | -7.09 Million AUD | -85.16% |
| 2018 Q2 | -5.01 Million AUD | -318.62% |
| 2018 Q4 | -4.54 Million AUD | 9.36% |
| 2018 FY | -5.33 Million AUD | -125.11% |
| 2017 FY | 21.24 Million AUD | 10.06% |
| 2017 Q4 | 2.29 Million AUD | -73.79% |
| 2017 Q2 | 8.75 Million AUD | 50.81% |
| 2016 Q4 | 5.8 Million AUD | -55.58% |
| 2016 FY | 19.3 Million AUD | 14.14% |
| 2016 Q2 | 13.06 Million AUD | 91.16% |
| 2015 FY | 16.91 Million AUD | -63.57% |
| 2015 Q4 | 6.83 Million AUD | -31.48% |
| 2015 Q2 | 9.97 Million AUD | 42.84% |
| 2014 Q4 | 6.98 Million AUD | -81.68% |
| 2014 FY | 46.43 Million AUD | 390.67% |
| 2014 Q2 | 38.11 Million AUD | 349.26% |
| 2013 Q4 | 8.48 Million AUD | 495.37% |
| 2013 Q2 | 1.42 Million AUD | 0.0% |
| 2013 FY | 9.46 Million AUD | 189.48% |
| 2012 Q4 | - AUD | 0.0% |
| 2012 FY | 3.26 Million AUD | -96.08% |
| 2011 FY | 83.31 Million AUD | 68.61% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 Q4 | - AUD | 0.0% |
| 2010 FY | 49.41 Million AUD | 567.3% |
| 2009 FY | -10.57 Million AUD | -39.94% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2008 FY | -7.55 Million AUD | 23.25% |
| 2007 FY | -9.84 Million AUD | 19.91% |
| 2007 Q4 | - AUD | 0.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2006 FY | -12.29 Million AUD | -103.4% |
| 2005 FY | -6.04 Million AUD | -42.8% |
| 2005 Q4 | - AUD | 0.0% |
| 2004 Q4 | - AUD | 0.0% |
| 2004 FY | -4.23 Million AUD | 28.86% |
| 2003 FY | -5.94 Million AUD | -55.07% |
| 2002 FY | -3.83 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.25 Million USD | -582.723% |
| Skye Bioscience, Inc. | -13.67 Million USD | 37.28% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 110.476% |
| Nascent Biotech, Inc. | -2.22 Million USD | -284.55% |
| Qrons Inc. | -643.67 Thousand USD | -1232.19% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1963.883% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -69.988% |
| BioStem Technologies, Inc. | -7.77 Million USD | -10.233% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1148.271% |
| CSL Limited | 3.7 Billion USD | 100.232% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 84.552% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 51.953% |
| Rebus Holdings, Inc. | -664 Thousand USD | -1191.416% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -542.115% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -2101.145% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 45.966% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 88.055% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 274.473% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -3176.327% |
| SQZ Biotechnologies Company | -75.82 Million USD | 88.691% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -200.824% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -458.25% |
| Mesoblast Limited | -84.14 Million USD | 89.81% |
| Marizyme, Inc. | -34.08 Million USD | 74.843% |
| Genus plc | 6.4 Million USD | 233.984% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 188.017% |
| Pharming Group N.V. | -4.87 Million USD | -75.734% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -331.668% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -820.677% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -2.695% |
| ContraFect Corporation | -56.88 Million USD | 84.927% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -88.266% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -511.63% |
| IMV Inc. | -38.67 Million USD | 77.826% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -211.723% |
| MultiCell Technologies, Inc. | -722.81 USD | -1186242.192% |
| ONE Bio Corp. | 13.68 Million USD | 162.676% |
| Accustem Sciences Inc. | -3.74 Million USD | -128.885% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 85.464% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -1675.134% |
| Q BioMed Inc. | -3.44 Million USD | -148.867% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 342.232% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -226.353% |
| Biomind Labs Inc. | -1 Million USD | -749.344% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 84.401% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -195.562% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -28.986% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -359.941% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -28529.14% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -343.7% |
| GB Sciences, Inc. | -1.42 Million USD | -503.657% |
| Alpha Cognition Inc. | -9.7 Million USD | 11.649% |
| HST Global, Inc. | -140.9 Thousand USD | -5985.574% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -662.286% |
| Halberd Corporation | -75.05 Thousand USD | -11325.716% |
| Enzolytics Inc. | -2.14 Million USD | -299.06% |
| Agentix Corp. | -1.37 Million USD | -525.111% |
| Resverlogix Corp. | -12.74 Million USD | 32.74% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -170.652% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 97.983% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -721.36% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -193.72% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -442.943% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -151.837% |
| AVAX Technologies, Inc. | 6.69 Million USD | 228.121% |
| Zenith Capital Corp. | -8.94 Million USD | 4.115% |
| Genscript Biotech Corporation | -415.79 Million USD | 97.938% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -49122.203% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -249.242% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -4899.722% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -327.733% |
| Kadimastem Ltd | -3.04 Million USD | -182.049% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -771.396% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -4624.908% |
| LadRx Corporation | -3.82 Million USD | -124.264% |
| Cell Source, Inc. | -4.32 Million USD | -98.25% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1148.271% |
| NovAccess Global Inc. | -2.46 Million USD | -247.622% |
| Affymax, Inc. | -15.04 Million USD | 43.008% |
| Itoco Inc. | -919.14 Thousand USD | -832.937% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -102.316% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -666.309% |
| Mobile Lads Corp. | -554.55 Thousand USD | -1446.299% |
| CytoDyn Inc. | -18.05 Million USD | 52.514% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -33968.335% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -3796.346% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -1418.444% |
| SYBLEU INC | -149.18 Thousand USD | -5648.09% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -372.108% |
| International Stem Cell Corporation | -663 Thousand USD | -1193.363% |
| Bioxytran, Inc. | -3.82 Million USD | -124.468% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -16189.894% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -42058.309% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 76.355% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -429.975% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -1065.343% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -175.635% |
| Neutra Corp. | -229.48 Thousand USD | -3636.611% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 51.109% |
| PureTech Health plc | -146.19 Million USD | 94.135% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 60.1% |
| IXICO plc | -1.43 Million USD | -496.729% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 9.651% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 92.96% |
| CSL Limited | 3.81 Billion USD | 100.225% |
| Cellectis S.A. | -108.85 Million USD | 92.123% |